Abstract:Abstract Background Endometrial cancer is the most common gynaecological cancer in high-income countries. Elevated body mass index (BMI) is an established modifiable risk factor for this condition and is estimated to confer a larger effect on endometrial cancer risk than any other cancer site. However, the molecular mechanisms underpinning this association remain unclear. We used Mendelian randomization (MR) to evaluate the causal role of 14 molecular risk factors (hormonal, metabolic and inflammatory markers) in endometrial cancer risk. We then evaluated and quantified the potential mediating role of these molecular traits in the relationship between BMI and endometrial cancer using multivariable MR. Methods Genetic instruments to proxy 14 molecular risk factors and BMI were constructed by identifying single-nucleotide polymorphisms (SNPs) reliably associated ( P < 5.0 × 10 −8 ) with each respective risk factor in previous genome-wide association studies (GWAS). Summary statistics for the association of these SNPs with overall and subtype-specific endometrial cancer risk (12,906 cases and 108,979 controls) were obtained from a GWAS meta-analysis of the Endometrial Cancer Association Consortium (ECAC), Epidemiology of Endometrial Cancer Consortium (E2C2) and UK Biobank. SNPs were combined into multi-allelic models and odds ratios (ORs) and 95% confidence intervals (95% CIs) were generated using inverse-variance weighted random-effects models. The mediating roles of the molecular risk factors in the relationship between BMI and endometrial cancer were then estimated using multivariable MR. Results In MR analyses, there was strong evidence that BMI (OR per standard deviation (SD) increase 1.88, 95% CI 1.69 to 2.09, P = 3.87 × 10 −31 ), total testosterone (OR per inverse-normal transformed nmol/L increase 1.64, 95% CI 1.43 to 1.88, P = 1.71 × 10 −12 ), bioavailable testosterone (OR per natural log transformed nmol/L increase: 1.46, 95% CI 1.29 to 1.65, P = 3.48 × 10 −9 ), fasting insulin (OR per natural log transformed pmol/L increase: 3.93, 95% CI 2.29 to 6.74, P = 7.18 × 10 −7 ) and sex hormone-binding globulin (SHBG, OR per inverse-normal transformed nmol/L increase 0.71, 95% CI 0.59 to 0.85, P = 2.07 × 10 −4 ) had a causal effect on endometrial cancer risk. Additionally, there was suggestive evidence that total serum cholesterol (OR per mg/dL increase 0.90, 95% CI 0.81 to 1.00, P = 4.01 × 10 −2 ) had an effect on endometrial cancer risk. In mediation analysis, we found evidence for a mediating role of fasting insulin (19% total effect mediated, 95% CI 5 to 34%, P = 9.17 × 10 −3 ), bioavailable testosterone (15% mediated, 95% CI 10 to 20%, P = 1.43 × 10 −8 ) and SHBG (7% mediated, 95% CI 1 to 12%, P = 1.81 × 10 −2 ) in the relationship between BMI and endometrial cancer risk. Conclusions Our comprehensive MR analysis provides insight into potential causal mechanisms linking BMI with endometrial cancer risk and suggests targeting of insulinemic and hormonal traits as a potential strategy for the prevention of endometrial cancer.

New role of fat-free mass in cancer risk linked with genetic predisposition

Saturated Fatty Acid Intake, Genetic Risk and Colorectal Cancer Incidence: A Prospective Cohort Study

The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank

Obesity, Fat Distribution and Risk of Cancer in Women and Men: A Mendelian Randomisation Study

Association of Body Composition with Risk of Overall and Site‐specific Cancers: A Population‐based Prospective Cohort Study

Fine-mapping of the HNF1B Multicancer Locus Identifies Candidate Variants That Mediate Endometrial Cancer Risk.

Cancer incidence in relation to body fatness among 0.5 million men and women: Findings from the China Kadoorie Biobank

Body fatness associations with cancer: evidence from recent epidemiological studies and future directions

Biomarker of Long-Chain n-3 Fatty Acid Intake and Breast Cancer: Accumulative Evidence from an Updated Meta-Analysis of Epidemiological Studies.

A genetic locus within the FMN1/GREM1 gene region interacts with body mass index in colorectal cancer risk

Interactions Between RASA2, CADM1, HIF1AN Gene Polymorphisms and Body Fatness with Breast Cancer: a Population-Based Case-Control Study in China.

Quantitative Association Between Body Mass Index and the Risk of Cancer: A Global Meta-analysis of Prospective Cohort Studies.

Body Fat Distribution and Risk of Breast, Endometrial, and Ovarian Cancer: A Two-Sample Mendelian Randomization Study

Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis

Body Weight Correlates with Molecular Variances in Cancer Patients

Observational and genetic associations between cardiorespiratory fitness and cancer: a UK Biobank and international consortia study

WHOLE GENOME SEQUENCING ANALYSIS OF BODY MASS INDEX IDENTIFIES NOVEL AFRICAN ANCESTRY-SPECIFIC RISK ALLELE

Height and Body Mass Index As Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.

Reassessing the causal role of obesity in breast cancer susceptibility: a comprehensive multivariable Mendelian randomization investigating the distribution and timing of exposure

The tumor multi-omic landscape of endometrial cancers developed on a germline genetic background of adiposity

Metabolic Obesity Phenotypes and Risk of Lung Cancer: A Prospective Cohort Study of 450,482 UK Biobank Participants